Patients with recurrent or persistent acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) are needed for a study to research the combination of a chemotherapy and immunotherapy drug

IRB/UVA Tracking #
20233
Principal Investigator
Michael K Keng
Contact
Cory Caldwell
Contact Email
Contact Phone
434.297.4182
Official Trial Title
A Phase 1 Study of Ipilimumab in Combination with Decitabine in Relapsed or Refractory Myelodysplastic Syndrome/Acute Myeloid Leukemia
Study Description

The University of Virginia Cancer Center is conducting a clinical research study for adults ages 18 and over who have recurrent or persistent acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS). This study will look at the effects of the combination of a chemotherapy drug (Decitabine) and an immunotherapy drug (Ipilimumab). The goal of the study is to find the best dose of ipilimumab that can be given safely in combination with decitabine for several courses and to determine what side effects are seen with this treatment.

Participation will last for approximately 2 years (1 year of treatment and 1 year of follow-up). Any procedures being done above and beyond standard of care will be provided at no cost to you or your insurance.

Additional information can be found here: https://clinicaltrials.gov/ct2/show/NCT02890329

Compensation

N/A